
Immunovant, Inc.: stock overview
Price
$31.77
November 20, 2026Market cap $6.5B
What Ploutos Investor adds for Immunovant
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from FY2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
It holds more cash than debt, by $722M. It pays no dividend.
From its SEC filings (latest fiscal year to March 31, 2026) and the price of November 20, 2026.
Its SEC filings- Market cap
- $6.5B
- 205M shares
- P/E
- –
- Revenue, 12 months
- –
- Net margin
- –
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Fiscal years in figures
IMVT's revenue, profit, cash flow and dividend with each year-end price, from FY2019 to FY2023, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $4.7B
- $6.5B
- Enterprise value
- $5.8B
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B 3-year median: 6.0
- 9.9
- FCF yield 3-year median: -8.0%
- –
- Earnings yield 3-year median: -11.2%
- –
Profitability
- Net margin
- –
- ROIC
- -46.8%
- ROIC, 5-year average
- -39.7%
- ROE
- -67.9%
Growth
Sorry, we do not have enough data
for the “Growth” group
Balance sheet
- Cash
- $722M
- Total debt
- $72.0K
- Of which operating leases
- $72.0K
- Net cash
- $722M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 7.31
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +20.1%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Immunovant, Inc.
- CIK
- 1764013
- Exchange
- NASDAQ
- Industry (SIC)
- 2836 · Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- March 31
- Latest annual report
- March 31, 2026
- Reporting currency
- USD
- Shares
- 205M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with IMVT
- JNJJohnson & Johnson+0,00%Compare with IMVT
- ABBVAbbVie+0,00%Compare with IMVT
- UNHUnitedHealth+0,00%Compare with IMVT
- MRKMerck & Company+0,00%Compare with IMVT
- AMGNAmgen+0,00%Compare with IMVT
- TMOThermo Fisher Scientific+0,00%Compare with IMVT
- ABTAbbott Laboratories+0,00%Compare with IMVT
The full analysis
What do Immunovant's filings show?
These are Immunovant's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is IMVT's market cap?
Immunovant, Inc.'s market cap is $6.5B, at a price of $31.77 on November 20, 2026 and 205M shares.
Does IMVT pay a dividend?
No. Immunovant paid no regular dividend over the last 12 months.
Where do the figures come from?
From Immunovant, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.